Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors

(2017) Maarten Arends et al.   PLoS One

Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases

(2016) Maria J. Ferraz et al.   FEBS LETTERS

Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study

(2016) Maarten Arends et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease

(2015) Bouwien E Smid et al.   JOURNAL OF MEDICAL GENETICS

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up

(2015) M. Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease

(2015) M. Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α

(2014) Kazuya Tsuboi et al.   GENETICS IN MEDICINE

Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance

(2014) B.E. Smid et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Outcomes of patients treated through the Canadian Fabry disease initiative

(2014) S.M. Sirrs et al.   MOLECULAR GENETICS AND METABOLISM

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

(2013) F. Weidemann et al.   JOURNAL OF INTERNAL MEDICINE

Fibrosis: a key feature of Fabry disease with potential therapeutic implications

(2013) Frank Weidemann et al.   Orphanet Journal of Rare Diseases

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain

(2013) Saskia M Rombach et al.   Orphanet Journal of Rare Diseases

Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry

(2012) H. Gold et al.   CLINICAL CHEMISTRY

Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine

(2012) Saskia M. Rombach et al.   HYPERTENSION

Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease

(2012) C. Tondel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

(2012) Saskia M. Rombach et al.   PLoS One

Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response

(2011) N. Dekker et al.   BLOOD

Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry

(2011) Ralf Krüger et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Fabry disease, enzyme replacement therapy and the significance of antibody responses

(2011) Patrick B. Deegan   JOURNAL OF INHERITED METABOLIC DISEASE

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients

(2011) Bouwien E Smid et al.   Orphanet Journal of Rare Diseases

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

(2010) Mariëlle J. van Breemen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

New Equations to Estimate GFR in Children with CKD

(2009) G. J. Schwartz et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative

(2009) S. Sirrs et al.   MOLECULAR GENETICS AND METABOLISM

Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3

(2008) Anouk C. Vedder et al.   MOLECULAR GENETICS AND METABOLISM

A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease

(2008) Bernard Bénichou et al.   MOLECULAR GENETICS AND METABOLISM

Elevated globotriaosylsphingosine is a hallmark of Fabry disease

(2008) J. M. Aerts et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA